Prof Trevor Marshall Foundation Staff
Posted: Tue Aug 9th, 2011 06:16
The group at Weill Cornell did not consider the possibility that their testing procedures might be confused by the thousands of other species present along with the Borrelia. I read this report, and although not junk science, it is of little practical use until their procedures become more precise, IMO. They really don't have much of a clue.
Rule #1 - whenever you see the word "antibodies" the research is most probably suspect.
Joined: Thu Nov 3rd, 2005
Location: Ontario Canada
Posted: Tue Aug 9th, 2011 09:06
Interesting Frenchie..thanks for posting this..
____________________ MP Feb 2008-Jan 2018. 1990 onwards-Neuro Lyme,
CO's, EBV. 2017 Dx- CIRS/Toxic Mold Illness|Inflammed Brain, Mast Cell Disorder.
Apr'15-25D= 9.20 ng|1-25D=17.50 pg
Mar'16-25D=63.00 ng|1-25D=42.98 pg
Sep'19-25D=30.83 ng|1-25D=78.40 pg
Joined: Thu Dec 30th, 2004
Location: Wroclaw, Poland
Posted: Fri Sep 16th, 2011 02:39
Dr Marshall, I saw in Your patent, that on page 3 there is information olmesartan docks into borrelia GPCR receptor.
Is this knowledge current ?
Do we know what this receptor does for borrelia ?
Last edited on Fri Sep 16th, 2011 02:41 by wrotek ____________________ Borreliosis(4 strains),Bartonella IgG only, reflux,headache TMJD ,chronic pain,chronic fatigue,depression 125D36 Ph1Sep05 Ph2Oct06 Ph3Apr07 in low lux NoIRs 25D<7 Oct06
Current time is 13:17 Page: 1 2 3 4 5
* We can help you understand chronic disease, but only your physician is licensed to give you medical care *
Powered by - Entire site Copyright © 2004-2020 Autoimmunity Research Foundation, All Rights Reserved
Page processed in 0.0394 seconds (89% database + 11% PHP). 18 queries executed.